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 Abstract 
 The Early Nutrition Academy and the Child Health Founda-
tion, in collaboration with the Committee on Nutrition, Euro-
pean Society for Paediatric Gastroenterology, Hepatology 
and Nutrition, held a workshop in March 2011 to explore 
guidance on acquiring evidence on the effects of nutritional 
interventions in infants and young children. The four objec-
tives were to (1) provide guidance on the quality and quan-
tity of evidence needed to justify conclusions on functional 
and clinical effects of nutrition in infants and young children 
aged  ! 3 years; (2) agree on a range of outcome measures 
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relevant to nutrition trials in this age group for which agreed 
criteria are needed; (3) agree on an updated ‘core data set’ 
that should generally be recorded in nutrition trials in infants 
and young children, and (4) provide guidance on the use of 
surrogate markers in paediatric nutrition research. The par-
ticipants discussed these objectives and agreed to set up six 
first working groups under the auspices of the Consensus 
Group on Outcome Measures Made in Paediatric Enteral Nu-
trition Clinical Trials (COMMENT). Five groups will aim to 
identify and define criteria for assessing key outcomes, i.e. 
growth, acute diarrhoea, atopic dermatitis and cows’ milk 
protein allergy, infections and ‘gut comfort’. The sixth group 
will review and update the ‘core data set’. The COMMENT 
Steering Committee will discuss and decide upon a method 
for reaching consensus which will be used by all working 
groups and plan to meet again within 2 years and to report 
and publish their conclusions. 
 Copyright © 2012 S. Karger AG, Basel 
 Background 
 Nutrition during infancy and early childhood (here 
defined as children aged up to 3 years) must meet the 
physiological nutrient requirements and support healthy 
growth and normal development. Considerable evidence 
has accumulated that infant feeding can markedly influ-
ence relevant functional and health outcomes on a short- 
and long-term basis  [1, 2] . Several unresolved questions 
and controversies exist among paediatricians, scientists 
and regulatory bodies on the quality and quantity of evi-
dence that is needed to draw firm conclusions on the 
presence of functional and clinical effects, as well as on 
the approaches to assess the relevance and impact of such 
effects for child and population health and for health eco-
nomic impact. Therefore, a workshop was held in March 
2011 under the auspices of the Early Nutrition Academy 
(www.early-nutrition.org) and the charitable Child 
Health Foundation (www.kindergesundheit.de), in col-
laboration with the Committee on Nutrition of the Euro-
pean Society for Paediatric Gastroenterology, Hepatolo-
gy and Nutrition (ESPGHAN; www.espghan.org). The 
main goal of the workshop was to prepare an approach 
for guidance on the ways to acquire good quality scien-
tific evidence on functional effects of nutritional inter-
ventions in infants and young children.
 Previously, several position papers and recommenda-
tions related to trials evaluating effects of nutritional in-
terventions in this age group have been published  [1, 3–8] 
( table 1 ).
 Despite these guidance documents and numerous 
published randomised controlled trials (RCTs), conclu-
sions on the efficacy and benefits of many nutritional in-
terventions and innovations used in infancy still remain 
uncertain and controversial, for example the addition of 
compounds with proposed probiotic and prebiotic effects 
to infant foods, as recently highlighted by the ESPGHAN 
Committee on Nutrition  [9] .
 There is still no agreement within the scientific com-
munity about how to best define and measure outcomes 
used in nutrition trials conducted in infants and young 
children. For example, a recent systematic review of 138 
RCTs reporting on paediatric acute diarrhoea found that 
64 different definitions of diarrhoea, 69 definitions of di-
arrhoea resolution and 46 unique primary outcomes were 
used  [10] . Thus, even in sound clinical trials on paediatric 
acute diarrhoea, many definitions are heterogeneous, lack 
evidence of validity and focus on indices that may not be 
relevant to child health or quality of life. Hence, the con-
clusions that can be drawn from the accumulated evidence 
are more restricted than they could otherwise be.
 The use of inappropriate outcome measures and/or 
their definitions may result in misleading information on 
the relevance of the outcome measure for infant health. It 
also may result in overestimation, underestimation or 
failure to reveal potential benefits of the intervention. 
Moreover, there are unresolved questions and controver-
sies among paediatricians, scientists and regulatory bod-
ies on the quality and quantity of evidence that is needed 
to draw firm conclusions on the presence of functional 
effects. The best approaches to assess the relevance and 
health economic impact of such effects for child and pop-
ulation health are also not clear. For example, questions 
have been raised on which conditions should be met by 
clinical trials, whether single or multiple trials are re-
quired to draw conclusions and whether documentation 
of functional effects requires the assessment of clinical 
endpoints, surrogate markers or the combination of both. 
These uncertainties could limit available resources for 
studies on innovation in paediatric nutrition that could 
benefit child health and well-being.
 Considering these issues, the workshop participants 
decided that consensus on a core set of outcomes with 
agreed definitions that should be measured and reported 
in nutrition trials is needed. Since the workshop was ar-
ranged under the auspices of the Early Nutrition Acade-
my and ESPGHAN, the group decided to call this initia-
tive the Early Nutrition Academy/ESPGHAN Consensus 
Group on Outcome Measures Made in Paediatric Enteral 
Nutrition Clinical Trials (to be known as COMMENT).
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 The COMMENT Approach 
 Problems to Be Addressed 
 The workshop participants agreed that problems re-
lated to the choice and definition of outcomes assessing 
the effects of the addition of new ingredients to infant 
formulae need to be urgently addressed. The recent com-
ment of the ESPGHAN Committee on Nutrition on sup-
plementation of infant formulae with compounds con-
sidered to have pre- and probiotic effects demonstrates 
these problems  [9] . Growth is typically assessed by an-
thropometric measurements, namely weight, length and 
head circumference. However, interpreting studies on 
the effects of probiotic or prebiotic supplementation of 
infant formulae on growth is difficult for several rea-
sons. Firstly, very few studies have analysed the effects of 
any specific probiotic strain and/or prebiotic compound. 
Secondly, several studies included a sample size that was 
too small, with insufficient power to identify relevant ef-
fects on growth as well as other outcomes. Finally, the 
follow-up periods in the trials were often too short. The 
choice and definitions of clinical outcomes differed, 
even those relating to the same domain (e.g. gastrointes-
tinal infections). Even if the same outcomes were mea-
sured, the chosen criteria for these outcomes were het-
erogeneous, often not widely agreed upon or just not re-
ported.
 Extrapolation of these specific conclusions relating to 
probiotics or prebiotics to other modifications of nutri-
tional interventions in infants and young children, e.g. 
the addition of any innovative ingredient to infant for-
mula, allowed agreement to be reached on several issues. 
The choice of outcomes, definitions of outcomes and in-
struments employed in trials to evaluate the safety and 
efficacy of infant formulae supplemented with innovative 
ingredients are heterogeneous, often lack evidence of reli-
ability and validity and sometimes focus on indices that 
may not be relevant to infants and their caregivers  [9] . 
Table 1. P osition papers and recommendations related to infant nutrition trials
Ref. No. Title of paper/report Key conclusions
3 The nutritional and safety assessment of 
breast milk substitutes and other dietary 
products for infants: a commentary by 
the ESPGHAN Committee on Nutrition
modifications of infant feeding regimens and dietary 
products need to be evaluated in clinical trials meeting 
accepted standards of scientific methodology
7 Infant Formula: Evaluating the Safety of 
New Ingredients
existing guidelines and regulations for evaluating the 
safety of conventional food ingredients (e.g. vitamins 
and minerals) added to infant formulas are not
sufficient to address the diversity of potential new
ingredients proposed by manufacturers to develop
formulas that mimic the perceived and potential
benefits of human milk
4 Characterisation of infant food
modifications in the European Union
general concepts on evaluating innovations and on
establishing evidence for benefits collated by a
multidisciplinary expert group
5 Core data for nutrition trials in infants: a 
discussion document – a commentary by 
the ESPGHAN Committee on Nutrition
proposed, for general discussion, a list of core data that 
should be recorded in nutrition trials and suggested 
principles for the identification of data required for 
studies with different outcome measures
6 Report of the Scientific Committee on 
Food on the Revision of Essential
Requirements of Infant Formulae and 
Follow-on Formulae
guidance on the evaluation of compositional
modifications of infant formulae or follow-on
formulae; general agreement that the choice of
measures of efficacy and safety will be determined by 
the nature of the study and the hypothesis being tested; 
examples for growth and neurodevelopment were
provided
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Mindful of this background, the COMMENT workshop 
participants agreed on the objectives outlined below.
 Overall Objectives of COMMENT 
 (1) To provide guidance on the level of quality and quan-
tity of evidence needed to justify conclusions of effects 
of nutrition in infants and young children on biologi-
cal function and clinical endpoints; 
 (2) to agree on a range of outcome measures relevant to 
nutrition trials in infants and young children for 
which agreed criteria are needed; 
 (3) to agree on an updated ‘core data set’ that should gen-
erally be recorded in nutrition trials in infants and 
young children, and 
 (4) to provide guidance on the use, strengths and limita-
tions of surrogate markers. 
 The Kick-Off Workshop in Tutzing 2011 
 The workshop spanned 2.5 days in March 2011 and 
was held in Tutzing near Munich, Germany. Workshop 
participants included researchers with knowledge in dif-
ferent areas including clinical trials, paediatric allergol-
ogy, infectious diseases, gut physiology, neonatology, 
neurodevelopment, nutrition and metabolism, paediatric 
gastroenterology and regulatory evaluation. Researchers 
working in the infant food industry and in a company 
developing and evaluating biomarkers were invited to at-
tend on the first day only to provide presentations on 
their experience and to answer questions regarding pre-
clinical and clinical evaluation. The group discussions 
and conclusions were held on the second and third day, 
without the presence of any representatives of industry. A 
list of the attendees from industry and their affiliations 
can be found at the end of this paper.
 The workshop participants reviewed and discussed 
the impressive achievements of the Outcome Measures in 
Arthritis Clinical Trials group, an international, infor-
mally organized network initiated in 1992 to improve 
outcome measurement in clinical studies in rheumatol-
ogy (including rheumatoid arthritis, osteoarthritis, os-
teoporosis, ankylosing spondylitis and gout). Chaired by 
an executive committee, it organises consensus confer-
ences in a 2-yearly cycle. Data-driven recommendations 
are prepared and updated by expert working groups  [11, 
12] . The workshop participants agreed that COMMENT 
should try to set similar objectives and attempt to func-
tion in a similar way for investigations in the field of ear-
ly nutrition.
 Discussion on Objective 1: To Provide Guidance 
on the Level of Quality and Quantity of Evidence 
Needed to Justify Conclusions on Functional and 
Clinical Effects of Nutrition in Infants and Young 
Children 
 What guidance can be given for conducting good 
quality studies in infant nutrition to demonstrate func-
tional effects?
 Type of Study and Type of Evidence 
 The workshop participants agreed that the preferred 
study design depended primarily, and most importantly, 
on the question which was being addressed. For example, 
although double-blind RCTs are generally accepted as the 
‘gold standard’, some research questions (such as the ben-
efits of breastfeeding) cannot always be answered by a 
randomised study, and other types of evidence (e.g. ob-
servational studies of high quality with adequate adjust-
ment for confounding) must be considered. Moreover, 
not all nutritional interventions can be securely double 
masked (e.g. protein hydrolysates may differ in taste and 
induced stool characteristics, and prebiotics or dietary fi-
bre may induce softer stools). The workshop participants 
concluded that obtaining a full body of good method-
ological quality evidence from all sources, with consis-
tent results, is most important. However, a larger quan-
tity of poor evidence can never replace a smaller quantity 
of good quality evidence.
 Understanding the mechanisms of beneficial effects is 
important, and this can help in the design of better RCTs. 
However, there are many examples of effects for which 
the detailed mechanisms are unknown (e.g. many of 
those in the cancer field). Therefore, showing a plausible 
mechanism or measuring a biomarker reflecting under-
lying mechanisms should be considered a very useful ad-
dition to good quality trial data but not a prerequisite for 
demonstrating effects of a nutritional intervention.
 The workshop participants agreed there was no con-
clusive current information that post-marketing surveil-
lance data (as obtained, say, by the infant food industry 
after a product launch) were valuable. So far, there is no 
indication that post-marketing surveillance data are use-
ful for documenting the benefit or safety of food products 
for infants and young children. Agreed standards have 
never been set for the conduct or reporting of post-mar-
keting surveillance, and there are too many confounding 
factors, such as the education level of subjects.
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 Trial Planning, Execution and Reporting 
 The workshop participants agreed that a consistent 
approach to the planning, conduct and reporting of RCTs 
is needed, not only with regard to study design but also 
in terms of the consistency of choosing study and control 
populations, taking samples from them and the storage 
of those samples.
 Trial and protocol registration prior to subject recruit-
ment is now an essential requirement for any trial in hu-
man subjects to avoid unintended duplication of trials. It 
prevents the suppression and selective reporting of re-
sults based on the interests of funders, unacknowledged 
alterations of pre-specified outcome measures and the 
failure to report relevant adverse events  [13] . The indis-
pensable need for such registration is also supported by 
the conclusions of a recent observational study of safety 
and efficacy trials for five drug categories. This showed 
that only two thirds of the results had been published 
within 2 years of the completion of the registered drug 
trials. Those funded by industry were less likely to be 
published, and those published were more likely to report 
positive outcomes than were trials funded by other sourc-
es  [14] . 
 The Consolidated Standards Of Reporting Trials 
statement gives guidelines for reporting trials  [15] . These 
guidelines were developed for drug trials, but several pa-
pers have provided guidance on designing clinical trials 
for specific functional food ingredients  [16–18] . Consen-
sus guidelines have recently been collated for designing, 
conducting and reporting human intervention studies to 
evaluate the health benefits of foods  [19] . These can be 
followed, to a great extent, in trials conducted with in-
fants and young children.
 Such consistency in all these aspects of trial design will 
not only ensure that high-quality trials are produced but 
will also ensure that banked samples from fully docu-
mented subjects can be available for future studies.
 Study, Control and Reference Populations 
 Matched Control Population 
 Considering the study population, the workshop par-
ticipants discussed whether it needed to be identical to 
the target population. They agreed that, in some cases, it 
may be possible to perform studies in a different age 
group. For example, results from comparative studies on 
the bioavailability of nutrients from different food sourc-
es and on their safety may often be suitable for extrapola-
tion to other age groups. However, if studies are per-
formed in a population with a high probability for an out-
come (e.g. family history of allergy, family history or 
genetic markers of celiac disease or type 1 diabetes, pop-
ulation with a high diarrhoea prevalence), care must be 
taken if the results are extrapolated to the general popula-
tion of healthy infants and young children.
 The gold-standard RCT requires a perfectly matched 
and randomised control population, but the workshop 
participants agreed that, in a few cases, some flexibility 
with respect to the choice of reference data could be al-
lowed. For example, in growth studies, the growth of the 
study population could be compared with growth curves 
from standard populations, including the recently pub-
lished WHO growth standards  [20] . However, the legiti-
macy of this strategy would depend on the research ques-
tion being asked. For example, evaluation of the suita-
bility of a particular novel ingredient would generally 
require an RCT with a control population fed the same 
formula but without the reference ingredient, whereas a 
formula modification aiming at matching the growth 
rate of breastfed populations might be compared to WHO 
growth standards.
 The workshop participants agreed that there are sci-
entific and ethical considerations that need to be taken 
into account in comparison of populations with different 
ethnic cultures and lifestyles, such as those from develop-
ing countries and less privileged segments of the popula-
tion. Different genetic and lifestyle backgrounds may 
mean that outcomes such as growth curves could not al-
ways be extrapolated to studies in Europe.
 What is ‘standard feeding’ of the control group? For 
example, in allergy prevention trials with modified for-
mula in children with a documented family history of 
allergic disease, is standard feeding a regular cows’ milk 
formula or a formula based on protein hydrolysates with 
previously documented allergy risk reduction? The an-
swer may differ depending on the standard feeding choic-
es in various settings or countries. However, it was agreed 
that ideally the control and study interventions should 
only differ in one component, namely the functional 
component of interest.
 Reference Population 
 Another alternative to the matched control population 
is the use of a reference population. Are populations of 
breastfed infants considered the ‘gold standard’, and 
should they generally be used as the reference? Should all 
studies aim at inclusion of reference breastfed popula-
tions? Although the workshop participants agreed that 
reference breastfed populations are often useful, they 
recognised the difficulties posed since consistently there 
are large sociodemographic differences relevant to health 
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between populations of breastfed and non-breastfed in-
fants. The workshop participants agreed that the choice 
of whether or not to include a breastfed group depends on 
the research question. If safety or efficacy of an added 
component is to be tested, it may suffice to compare two 
formula groups fed formula with or without the added 
component. If, however, the goal is to demonstrate simi-
larity to clinical outcomes in breastfed populations, then 
inclusion of a reference breastfed group should be consid-
ered. In some instances, comparison of results to data 
from previously studied reference breastfed populations 
or growth reference data of breastfed populations can be 
adequate.
 Other Considerations 
 Practicalities might also determine the starting age 
for trial participants. Clinical studies that assess param-
eters such as growth, and safety and efficacy of an infant 
formula may provide the most informative results when 
the formula is fed as the sole source of nutrition from 
birth. This is the period with the most rapid growth, 
highest nutrient requirements per kilogram of body 
weight and highest sensitivity to an unbalanced supply. 
However, in Europe, it has now become very difficult to 
enroll infants fed formula from birth since, fortunately, 
most healthy infants are breastfed after birth. The estab-
lished approach for an infant growth study is to power it 
to detect differences in growth using 0.5 standard devia-
tion in a study starting from birth with a duration of 3 
months  [5] . If enrolment into a study has to be started at 
a later time point after an initial period of breastfeeding, 
e.g. during the second or third month of life, studies may 
need to be powered to detect smaller effect sizes to docu-
ment potential effects of food components on growth at 
an age with lower nutrient needs than those immediate-
ly after birth.
 As there is no scientific rationale to support a strict 
distinction between development in infants under and 
above 6 months of age with respect to the effect of factors 
such as nutrients on growth and development, to what 
extent can data collected in infants 0–6 months of age be 
extrapolated to infants 6–12 months of age? The work-
shop participants agreed that this should be decided on a 
case-by-case basis and that it was best left for discussion 
in the specific working groups (see below).
 The importance of deciding upon a statistical plan for 
analysing results at the outset of a trial was emphasised. 
The level for statistical significance should also be agreed 
at this point. The workshop participants agreed that this 
level did not always have to be p  ! 0.05, especially in 
studies of healthy populations, but other levels of signif-
icance might be chosen depending on the given condi-
tions.
 Transparency of approach, namely registration and/or 
publication of the study design and primary outcome 
measures at the outset, is essential. There is no problem 
with assessing more than one health outcome in a trial, 
as long as this is decided upon and transparently report-
ed at the outset. Assessing multiple primary outcomes 
should be reflected in the power analysis and increases 
the number of subjects needed in the trial. Analysing sec-
ondary outcomes is also permissible as long as this is 
made clear at the outset.
 Open-Label Extension to Trials 
 Quite often subjects participating in RCTs are fol-
lowed up further, after the un-blinding of the trial, to ex-
plore potential longer-term effects of the intervention. 
Such ‘open-label’ extensions of RCTs are obviously sub-
ject to potential bias due to lack of blinding. An even more 
important threat to validity may be dropouts from the 
sample randomised in the preceding RCT  [21, 22] . None-
theless, follow-up of the long-term health effects of early 
nutritional interventions is encouraged, since these out-
comes are of great public health interest and this type of 
information is currently still scarce.
 Replication of Trials 
 The workshop participants discussed whether replica-
tion of clinical trial results in an independent second tri-
al was generally necessary. Replication may not be easy if 
there is lack of scientific novelty or little interest from po-
tential sponsors if a commercially available ingredient 
showed positive effects in a previous study. However, its 
importance is demonstrated by contrasting results in rep-
licated studies. For example, Kopp et al.  [23] evaluated the 
effect of using  Lactobacillus  GG for the primary preven-
tion of atopic dermatitis following a protocol almost iden-
tical to that used in a study  [24] which had reported a 
preventive effect on the development of atopic eczema. 
However, the later investigators found no benefit of  Lac-
tobacillus  GG use in the prevention of atopic dermatitis 
 [23] .
 Consequently, the workshop participants agreed that 
sometimes one trial may suffice, but sometimes more 
than one trial may be necessary. At least two independent 
adequate trials with similar outcomes are often needed to 
provide convincing evidence and to change practice, but 
this is not always achievable, particularly if a large sample 
size or long-term follow-up is needed to test a specific hy-
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pothesis. The participants discussed whether replication 
in a second, more or less identical, study and burdening 
another population with, say, blood samples, was ethical? 
It was agreed that the best option was to repeat the trial 
but to modify it so that, say, another primary outcome is 
added to those tested before.
 Growth Studies 
 Growth has always been an important outcome in nu-
tritional intervention studies. Traditionally, it has been 
regarded as a safety outcome to ensure that new nutri-
tional products adequately supported growth during the 
important first years of life. With the obesity epidemic 
and the increasing focus on long-term effects of early 
nutrition and early growth, interpretation of growth 
data during the first years of life has become more com-
plex. The workshop discussion suggested that perhaps 
growth studies are not always necessary when function-
al effects are being investigated, and that perhaps growth 
studies are only needed under specific circumstances, 
for example the modification of protein content or qual-
ity, or the addition of complex carbohydrates, which 
might modify the bioavailability of other formula com-
pounds.
 Safety 
 The workshop participants stressed the overall im-
portance of checking safety at the same time as function-
ality.
 Comparison between Quality and Quantity of 
Evidence to Draw Conclusions in the Pharma 
Industry and the Infant Food Industry 
 The participation of infant food industry representa-
tives on day 1 allowed the discussion of the following 
question: ‘Is the same high evidence level necessary to 
document functional effects of food, e.g. the promotion 
of a functional development or of the risk reduction of an 
allergic manifestation, as compared to the effects of ther-
apeutic drugs?’.
 The workshop participants agreed that the food indus-
try is not the same as the pharma industry but that the 
‘controls/guidance’ for the  infant food industry have 
many parallels with the pharma industry  [25] . This is due 
to the sensitive age group and the need to ensure the high-
est possible level of safety for feeding infants and young 
children. It is therefore useful to consider pharma, with 
its tight regulations, as a model. Having said this, the 
workshop participants recognised that the context within 
which the infant food industry operates is much more 
complicated than that in which the pharma industry op-
erates for the following reasons:
 • A reductionist approach is usually used for pharma, 
but a holistic approach is always needed for food. How-
ever, investigating the effects of feeding infants and 
follow-up formulas is simpler than looking at the ef-
fects of food on adults because the diet is less hetero-
geneous. 
 • Pharma products are generally used for the treatment 
of disease in those who are already ill, whereas func-
tional food products (including those for infants) are 
mainly targeted at healthy people, aiming at securing 
optimal health and development and lowering disease 
risk. 
 • Pharma products lend themselves more to being tested 
in double-blind RCTs compared with food ingredi-
ents, which are sometimes difficult to mask. Compli-
ance tends to be better in drug trials, in which par-
ticipating subjects suffer from a burden of disease and 
are usually closely supervised by a health care profes-
sional. 
 • The influence of age and ethnicity is often less impor-
tant in pharma trials compared with their influence in 
food trials in infants and young children, where age 
and ethnicity are often closely associated with nutrient 
supply and status. 
 Within the infant food industry, demonstration of 
safety has always been paramount, but the current cli-
mate demands proof of efficacy much more than ever be-
fore.
 Discussion on Objective 2: To Agree on a Range 
of Outcome Measures Relevant to Nutrition Trials 
in Infants and Young Children for Which Agreed 
Criteria Are Needed 
 Which outcomes could be assessed in clinical trials?
 The presentations and discussions covered a range of 
outcome measures which could be classified as shown in 
 table 2. 
 Points of Ambiguity and Questions about Outcome 
Measures 
 The workshop participants recognised that there is 
confusion and ambiguity between clinical endpoints, in-
termediary endpoints and markers. They agreed that the 
following are all relevant questions: Which clinical out-
come parameters can be considered indicative for im-
proving function and subsequently beneficial for infant 
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health? Can we provide criteria for effect sizes that are 
relevant? Should we consider the number needed to treat? 
Which factors in infancy/early childhood should be con-
sidered to predict later disease risk? What is the value of 
predefined secondary outcomes compared to predefined 
primary outcomes?
 General Principles for Outcome Measures 
 The workshop participants decided that it would be 
best to discuss these questions in detail in specific work-
ing groups devoted to particular outcomes (see below). 
However, they were able to agree some general principles:
 • it is a priority to agree upon common definitions for 
outcome measures, and this can realistically be 
achieved in parallel working groups; 
 • a good outcome measure which is easy to measure and 
is clearly defined (diarrhoea would make a good ex-
ample if this can be achieved) will make the use of 
markers redundant for that particular health outcome, 
and 
 • markers for health outcomes with good outcome mea-
sures could still be needed if we need to use that mark-
er to predict future events (like growth). 
 Discussion on Objective 3: To Agree on an Updated 
‘Core Data Set’ That Should Generally Be Recorded 
in Nutrition Trials in Infants and Young Children 
 A discussion document from the ESPGHAN Com-
mittee on Nutrition published in 2003 has suggested a 
core data set for nutrition trials in infants  [5] . This docu-
ment suggests checklists for identification data and core 
data for all studies of infants, as well as for studies of in-
fants born preterm  [5] . It has been used and referred to by 
several investigators. 
 It was agreed that the COMMENT working group will 
join forces with the ESPGHAN Committee on Nutrition 
in order to publish a revised ESPGHAN position paper 
on these matters.
 An updated core data set will ensure that full details 
of body composition with a full clinical chemical profile 
are always collected in trials in infants and young chil-
dren. This will then facilitate comparison of results from 
studies, for example in meta-analyses. However, all work-
shop participants agreed that, although it was essential to 
collect comprehensive core data, in doing so, the burden 
on parents and children must be kept to a minimum.
 Discussion on Objective 4: To Provide Guidance on 
the Use, Strengths and Limitations of Markers 
 Background 
 The workshop participants reviewed how the nature 
and characterisation of markers, in the context of explor-
ing the evidence needed to support health claims on 
foods, were initially addressed initially in the EC project 
Functional Food Science in Europe  [26] and then in the 
EC project Process for the Assessment of Scientific Sup-
port for Claims on Foods  [27] , which explored further 
how the markers would be used as part of the strategic 
essence of the portfolio of evidence submitted to substan-
tiate a health claim.
 The two concerted actions deliberately avoided using 
the term ‘biomarker’ because they wish to convey the mes-
sage that any relevant phenomenon or outcome could 
serve as a ‘marker’. Markers can be used to give an indica-
tion of intake (external exposure or dosage), body burden 
(internal exposure, ‘status’), systemic intermediate metab-
olism and the production of metabolites (both active and 
inactive) or intermediate functional effects, leading to the 
ultimate desired outcome. If the latter cannot be mea-
sured, then a marker can be used as a ‘surrogate endpoint’. 
Table 2. C lassification or outcome measures
Growth
Functional outcomes, development and health, e.g. gut
physiology, permeability or inflammation, stool bacteria, stool 
patterns
Neurodevelopment
– Sensory function (e.g. vision, auditory)
– Motor function
– Cognitive function
Immune response
– Clinical endpoints versus biomarkers
Disease risk reduction
– Infectious diseases, e.g. gastroenteritis, upper respiratory tract 
infection, urinary tract infection
– Eczema/atopic eczema
– Food allergy
– Other allergic disorders, e.g. asthma, wheezing, eosinophilic 
gastroenteropathy/oesophagitis
– Coeliac disease
– Type 1 diabetes
– Autoimmune diseases, inflammatory bowel diseases
– Prematurity-related disorders (necrotising enterocolitis,
intestinal failure)
– Other chronic diseases (obesity, cardiovascular disease)
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This sequence is completely analogous to the absorption, 
distribution, metabolism and excretion model of pharma-
cokinetics or toxicokinetics, and strategies for identifying, 
if necessary, intermediate markers for nutritional studies 
can be learned from experience in these fields.
 If markers represent an event directly or causally in-
volved in the process under study, they have been called 
‘factors’, whereas if a direct functional correlation has not 
been demonstrated and they may in fact be bystanders or 
associated phenomena, they are called ‘indicators’. Dis-
cussions about whether or not markers are indicators or 
factors come from discussions about observational epide-
miological studies and are not so relevant to discussion 
of trials.
 Thus, there is a need to give serious thought to the va-
lidity of markers in relation to their expected purpose in 
any experimental study. The fundamental criteria for 
markers in any clinical study are generic. Markers can be 
chemical, biochemical, physiological (i.e. addressing per-
formance or adaptive capacity), observational or behav-
ioural, in short, anything that can be objectively mea-
sured. As such, they therefore should be feasible, valid, 
reproducible, sensitive and specific. The following char-
acteristics apply equally well to all types of marker:
 • markers should be measurable at relatively immediate 
time points to be useful in assessing interventions in a 
reasonable timescale; 
 • markers should be rigorously validated and amenable 
to standard quality control procedures; 
 • they should be clearly linked to the phenomena in-
volved in the biological process being studied; ideally, 
usually as part of the validation, markers other than 
the endpoint should have an obvious role in the mech-
anistic pathway leading to the outcome being studied; 
 • markers should usually be gained from an easily ac-
cessible material, by a minimally invasive and ethical 
procedure; 
 • markers may need to be validated from mechanistic 
studies in animal models and cellular studies; 
 • markers need not be single static measurements; they 
may represent dynamic responses such as clearance 
studies, changes in enzyme function or signal trans-
duction, and 
 • static and dynamic markers might also be based on 
objective measurements of psychological and physical 
performance and subjective assessments of quality-of-
life or similar outcomes. 
 Above all, investigators should focus on study design 
and on the selection of appropriate phenomena or char-
acteristics that can be measured to investigate or demon-
strate a specific causal relationship. Thus, markers and 
their roles can be identified within the context of the 
study design.
 Workshop Decisions 
 The workshop participants decided they could only 
give some general directions on markers at this stage. 
Firstly, the workshop participants agreed that they would 
use the term ‘marker’ rather than ‘biomarker’ for the rea-
sons given above.
 Secondly, it is important to distinguish markers of ex-
posure (external and internal) to a functional component 
from markers which could be predictive of the effect of 
that component on functional outcome or reduced risk of 
disease. A variety of exposure markers for dietary intake 
of nutrients and non-nutrients have been reported and to 
some extent validated for infants and young children 
 [28–30] .
 The main point is to choose markers that have been 
proven to correlate with clinical outcome. However, there 
are far fewer data on markers for outcome in early child-
hood than there are for adults (for example, in adults, 
high serum low-density lipoprotein cholesterol levels are 
accepted as a predictor of cardiovascular disease risk). At 
present, there are only limited validated markers of clin-
ical outcomes relevant for infant nutrition studies (e.g. 
growth, adiposity, allergy). Whenever markers exist, 
based on known mechanisms of a dietary component ef-
fect on a clinical endpoint, it would obviously be most 
useful to include these in any clinical trials. Since this is 
not often the case, the current focus is on the assessment 
of clinical endpoints. Clearly, identification of a marker 
is not a prerequisite for conclusively demonstrating effi-
cacy based on documentation of clinical endpoint effects.
 New exciting opportunities for developing informa-
tive markers may arise from systems biology (metabolo-
mic and bioinformatic methodology) and mathematic 
modelling, which might help strategically develop meta-
bolic maps and thus identify good exposure and predic-
tive markers.
 Next Steps 
 Working Groups 
 The workshop participants agreed that six working 
groups should be set up as soon as possible and that oth-
ers (such as immune function) might be considered later. 
Leaders of these working groups were agreed and are 
shown in  table 3 .
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 The working group leaders will recruit other experts 
as needed, but the working groups will remain small, 
with usually no more than 4–5 members. Their aim is to 
identify and define criteria for assessing key outcomes. 
The groups will perform a systematic review at the outset 
to inform on the current heterogeneity of outcomes. The 
COMMENT Steering Committee will discuss and decide 
upon a method for reaching consensus which will be used 
by all working groups. A section of the ESPGHAN web-
site will be dedicated to COMMENT to enable good com-
munication between working groups and their members.
 Consensus-Forming Techniques 
 The COMMENT Steering Committee will discuss 
and decide upon a method for reaching consensus which 
will be used by all working groups. Several were suggest-
ed at the workshop, including the nominal group tech-
nique, the Delphi technique and the decision support ma-
trix technique. The working groups and the Steering 
Committee will decide on the strategies for future meet-
ings and publications.
 Dissemination and Exploitation of COMMENT 
Discussions and Consensus to Stakeholders 
 The COMMENT workshop participants agreed that 
their conclusions should reach clinicians/scientists who 
are involved in preclinical and clinical studies, scientific 
societies and bodies providing recommendations (e.g. 
ESPGHAN, American Academy of Pediatrics), risk as-
sessment bodies (e.g. European Food Safety Authority, 
national bodies such as Agence nationale de sécurité san-
itaire de l’alimentation, de l’environnement et du travail 
(France), Bundesinsitut für Risikobewertung (Germany), 
Food and Drug Administration (USA), Food Safety Au-
thority (UK) ) and risk management bodies (e.g. Euro-
pean Commission, Codex Alimentarius, national bod-
ies).
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Table 3. W orking groups that were agreed to be set up
Working group Proposed leader
Growth Prof. Kim Fleischer Michaelsen
Acute diarrhoea Prof. Hania Szajewska
Atopic dermatitis  and cows’ 
milk protein allergy
Prof. Christophe Dupont
Infections (e.g. upper/lower
respiratory tract, urinary tract)
Prof. Alfredo Guarino
‘Gut comfort’ (e.g. colic,
constipation, bloating)
Prof. Marc Beningna
Review of core data set Prof. Bert Koletzko
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